Recent Research Analysts’ Ratings Changes for Seaport Therapeutics (SPTX)

Several analysts have recently updated their ratings and price targets for Seaport Therapeutics (NASDAQ: SPTX):

• 5/27/2026 – Seaport Therapeutics was upgraded by Zacks Research to “hold”.
• 5/26/2026 – Seaport Therapeutics is now covered by Citigroup Inc.. They set a “buy” rating and a $35.00 price target on the stock.
• 5/26/2026 – Seaport Therapeutics was downgraded by BNP Paribas Exane to “market perform”.
• 5/26/2026 – Seaport Therapeutics is now covered by Stifel Nicolaus. They set a “buy” rating and a $30.00 price target on the stock.
• 5/26/2026 – Seaport Therapeutics was given a new $42.00 price target by Seaport Research Partners.
• 5/26/2026 – Seaport Therapeutics is now covered by JPMorgan Chase & Co.. They set an “overweight” rating and a $42.00 price target on the stock.
• 5/26/2026 – Seaport Therapeutics is now covered by Leerink Partners. They set an “outperform” rating and a $35.00 price target on the stock.
• 5/9/2026 – Seaport Therapeutics was upgraded by Wall Street Zen to “hold”.

Insider Activity

In related news, major shareholder Arch Venture Partners Xii, Llc purchased 1,100,000 shares of Seaport Therapeutics stock in a transaction dated Monday, May 4th. The stock was acquired at an average cost of $18.00 per share, with a total value of $19,800,000.00. Following the completion of the transaction, the insider directly owned 6,294,951 shares of the company’s stock, valued at $113,309,118. This trade represents a 21.17% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.